188 related articles for article (PubMed ID: 22281721)
1. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.
Björkman S; Ahlén V
Eur J Clin Pharmacol; 2012 Jun; 68(6):969-77. PubMed ID: 22281721
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
Björkman S
Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
Björkman S
Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.
Brekkan A; Berntorp E; Jensen K; Nielsen EI; Jönsson S
J Thromb Haemost; 2016 Apr; 14(4):724-32. PubMed ID: 26806557
[TBL] [Abstract][Full Text] [Related]
8. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
9. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
[TBL] [Abstract][Full Text] [Related]
11. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A; Fischer K; Blanchette V; Rangarajan S; Young G; Morfini M;
Thromb Haemost; 2017 Jun; 117(6):1023-1030. PubMed ID: 28357444
[TBL] [Abstract][Full Text] [Related]
12. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
Tardy B; Lambert T; Chamouni P; Montmartin A; Trossaert M; Claeyssens S; Berger C; Ardillon L; Gay V; Delavenne X; Harroche A; Chelle P
Haemophilia; 2022 Jul; 28(4):542-547. PubMed ID: 35420242
[TBL] [Abstract][Full Text] [Related]
13. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
Carlsson M; Björkman S; Berntorp E
Haemophilia; 1998 Mar; 4(2):83-8. PubMed ID: 9873843
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM; Rendo P; Smith L; Altisent C
Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis in factor IX deficiency product and patient variation.
Kisker CT; Eisberg A; Schwartz B;
Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
[TBL] [Abstract][Full Text] [Related]
16. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
18. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
19. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
